双特异性抗体药物在肺癌治疗中的研究进展
Research Progress of Bispecific Antibody Drugs in Lung Cancer Therapy
DOI: 10.12677/acm.2025.15113293, PDF,   
作者: 彭叶微：右江民族医学院研究生学院，广西 百色；李也鹏*：右江民族医学院附属医院肿瘤放疗科，广西 百色
关键词: 双特异性抗体；非小细胞肺癌；小细胞肺癌；临床试验；治疗靶点；Bispecific Antibody； Non-Small Cell Lung Cancer； Small Cell Lung Cancer； Clinical Trial； Therapeutic Target
摘要: 肺癌是全球发病率和死亡率最高的恶性肿瘤之一。双特异性抗体(BsAb)通过同时靶向两个抗原，在克服肿瘤异质性、提升治疗精准性方面展现独特优势，为肺癌治疗带来新方向。本文系统介绍BsAb的结构特征、作用机制及分类，重点综述其在小细胞肺癌(SCLC)与非小细胞肺癌(NSCLC)中的研究进展，包括针对EGFR/MET、PD-1/VEGF、DLL3/CD3等靶点的药物研发(如已获批的Amivantamab、Tarlatamab)及III期临床试验关键成果，分析研发中的技术与临床挑战及应对策略，最后展望未来发展方向，为肺癌精准治疗提供参考。
Abstract: Lung cancer is one of the leading causes of cancer-related morbidity and mortality worldwide. Bispecific antibodies (BsAbs), by simultaneously targeting two antigens, offer unique advantages in overcoming tumor heterogeneity and improving treatment precision, bringing new directions to lung cancer treatment. This article systematically introduces the structural characteristics, mechanisms of action, and classification of BsAbs, focusing on a review of their research progress in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), including drug development targeting EGFR/MET, PD-1/VEGF, DLL3/CD3 (such as the approved Amivantamab and Tarlatamab) and key findings from Phase III clinical trials. It analyzes the technical and clinical challenges in development and corresponding strategies, and finally looks forward to future development directions, providing a reference for the precision treatment of lung cancer.
文章引用：彭叶微, 李也鹏. 双特异性抗体药物在肺癌治疗中的研究进展[J]. 临床医学进展, 2025, 15(11): 1859-1868. https://doi.org/10.12677/acm.2025.15113293

参考文献

[1] Zheng, R., Zhang, S., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. [Google Scholar] [CrossRef] [PubMed]
[2] Suurs, F.V., Lub-de Hooge, M.N., de Vries, E.G.E. and de Groot, D.J.A. (2019) A Review of Bispecific Antibodies and Antibody Constructs in Oncology and Clinical Challenges. Pharmacology & Therapeutics, 201, 103-119. [Google Scholar] [CrossRef] [PubMed]
[3] Paz-Ares, L., Champiat, S., Lai, W.V., Izumi, H., Govindan, R., Boyer, M., et al. (2023) Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. Journal of Clinical Oncology, 41, 2893-2903. [Google Scholar] [CrossRef] [PubMed]
[4] Cho, B.C., Simi, A., Sabari, J., Vijayaraghavan, S., Moores, S. and Spira, A. (2023) Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-Epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications. Clinical Lung Cancer, 24, 89-97. [Google Scholar] [CrossRef] [PubMed]
[5] Pang, X., Huang, Z., Zhong, T., Zhang, P., Wang, Z.M., Xia, M., et al. (2023) Cadonilimab, a Tetravalent PD-1/CTLA-4 Bispecific Antibody with Trans-Binding and Enhanced Target Binding Avidity. mAbs, 15, Article 2180794. [Google Scholar] [CrossRef] [PubMed]
[6] Wu, W., Chia, T., Lu, J., Li, X., Guan, J., Li, Y., et al. (2023) IL-2Rα-Biased Agonist Enhances Antitumor Immunity by Invigorating Tumor-Infiltrating CD25+CD8+ T Cells. Nature Cancer, 4, 1309-1325. [Google Scholar] [CrossRef] [PubMed]
[7] Weisser, N.E., Sanches, M., Escobar-Cabrera, E., O’Toole, J., Whalen, E., Chan, P.W.Y., et al. (2023) An Anti-HER2 Biparatopic Antibody That Induces Unique HER2 Clustering and Complement-Dependent Cytotoxicity. Nature Communications, 14, Article No. 1394. [Google Scholar] [CrossRef] [PubMed]
[8] Han, L., Wang, K., Jiang, Z., Guo, X. and Yu, J. (2025) Recent Development in Bispecific Antibody Immunotherapy for Hematological Malignancies. Critical Reviews in Oncology/Hematology, 212, Article 104752. [Google Scholar] [CrossRef] [PubMed]
[9] Ross, S.L., Sherman, M., McElroy, P.L., Lofgren, J.A., Moody, G., Baeuerle, P.A., et al. (2017) Bispecific T Cell Engager (BiTE®) Antibody Constructs Can Mediate Bystander Tumor Cell Killing. PLOS ONE, 12, e0183390. [Google Scholar] [CrossRef] [PubMed]
[10] Liu, Z., Chu, H., Zhao, W., Yang, C., Liu, T., Shen, N., et al. (2025) Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4. Advanced Science, 12, e2408899. [Google Scholar] [CrossRef] [PubMed]
[11] Zhou, F., Ben, Y., Jiang, H., Tan, S., Mu, G., Zha, Z., et al. (2024) A Novel Dual-Fc Bispecific Antibody with Enhanced Fc Effector Function. Biochemistry, 63, 958-968. [Google Scholar] [CrossRef] [PubMed]
[12] Goulet, D.R., Zwolak, A., Williams, J.A., Chiu, M.L. and Atkins, W.M. (2020) Design and Characterization of Novel Dual Fc Antibody with Enhanced Avidity for Fc Receptors. Proteins: Structure, Function, and Bioinformatics, 88, 689-697. [Google Scholar] [CrossRef] [PubMed]
[13] Hushmandi, K., Einollahi, B., Lee, E.H.C., Sakaizawa, R., Glaviano, A., Reiter, R.J., et al. (2025) Bispecific Antibodies as Powerful Immunotherapeutic Agents for Urological Cancers: Recent Innovations Based on Preclinical and Clinical Evidence. International Journal of Biological Sciences, 21, 1410-1435. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, W., Qiu, T., Li, F. and Ren, S. (2023) Current Status and Future Perspectives of Bispecific Antibodies in the Treatment of Lung Cancer. Chinese Medical Journal, 136, 379-393. [Google Scholar] [CrossRef] [PubMed]
[15] Park, K., Haura, E.B., Leighl, N.B., Mitchell, P., Shu, C.A., Girard, N., et al. (2021) Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39, 3391-3402. [Google Scholar] [CrossRef] [PubMed]
[16] Zhuang, W., Zhang, W., Wang, L., Xie, L., Feng, J., Zhang, B., et al. (2023) Generation of a Novel SORT1 × HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal of Molecular Sciences, 24, Article 16056. [Google Scholar] [CrossRef] [PubMed]
[17] Passaro, A., Wang, J., Wang, Y., et al. (2024) Amivantamab Plus Chemotherapy with and without Lazertinib in EGFR-Mutant Advanced NSCLC after Disease Progression on Osimertinib: Primary Results from the Phase III MARIPOSA-2 Study. Annals of Oncology, 35, 77-90. [Google Scholar] [CrossRef] [PubMed]
[18] Leighl, N.B., Akamatsu, H., Lim, S.M., Cheng, Y., Minchom, A.R., Marmarelis, M.E., et al. (2024) Subcutaneous versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study. Journal of Clinical Oncology, 42, 3593-3605. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, L., Luo, Y., Ren, S., Zhang, Z., Xiong, A., Su, C., et al. (2024) A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First-or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. Journal of Thoracic Oncology, 19, 465-475. [Google Scholar] [CrossRef] [PubMed]
[20] Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., et al. (2024) Ivonescimab Plus Chemotherapy in Non–small Cell Lung Cancer with EGFR Variant. Journal of the American Medical Association, 332, 561-570. [Google Scholar] [CrossRef] [PubMed]
[21] Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., et al. (2025) Ivonescimab versus Pembrolizumab for Pd-L1-Positive Non-Small Cell Lung Cancer (Harmoni-2): A Randomised, Double-Blind, Phase 3 Study in China. The Lancet, 405, 839-849. [Google Scholar] [CrossRef] [PubMed]
[22] Schram, A.M., Goto, K., Kim, D., Macarulla, T., Hollebecque, A., O’Reilly, E.M., et al. (2025) Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. New England Journal of Medicine, 392, 566-576. [Google Scholar] [CrossRef] [PubMed]
[23] Ahn, M., Cho, B.C., Felip, E., Korantzis, I., Ohashi, K., Majem, M., et al. (2023) Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. New England Journal of Medicine, 389, 2063-2075. [Google Scholar] [CrossRef] [PubMed]
[24] Lau, S.C.M., Ahn, M.J., Moskovitz, M., et al. (2024) Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-Immunotherapy for ES-SCLC: Dellphi-303 Phase 1b Study. Journal of Thoracic Oncology, 19, S31-S32. [Google Scholar] [CrossRef] 
[25] Mountzios, G., Sun, L., Cho, B.C., Demirci, U., Baka, S., Gümüş, M., et al. (2025) Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. New England Journal of Medicine, 393, 349-361. [Google Scholar] [CrossRef] [PubMed]
[26] 程颖. PM8002(BNT327)PD-L1×VEGF双特异性抗体二线治疗小细胞肺癌的II期研究[C]//欧洲肿瘤内科学会, 国际肺癌研究协会. 2025年欧洲肺癌大会(ELCC). 2025.
[27] Huang, Y., Zhang, L., Ma, Y., Zhao, Y., Fang, W., Zhao, H., et al. (2025) Phase I Study of Iza-Bren (BL-B01D1), an EGFR X HER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Small Cell Lung Cancer (SCLC). Journal of Clinical Oncology, 43, Article 3002. [Google Scholar] [CrossRef] 
[28] Ingavat, N., Dzulkiflie, N., Liew, J.M., Wang, X., Leong, E., Loh, H.P., et al. (2024) Investigation on Environmental Factors Contributing to Bispecific Antibody Stability and the Reversal of Self-Associated Aggregates. Bioresources and Bioprocessing, 11, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
[29] Rilvegostomig Investigators (2025) Phase I/II ARTEMIDE-01 Study of AZD2936 (PD-1 × TIGIT Bispecific Antibody) in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 20, 1456-1465.
[30] Yang, C., Zhang, J., Liu, M., et al. (2024) Preclinical Evaluation of a Novel PD-L1 × TIGIT Bispecific Antibody with Fc Silencing in Non-Small Cell Lung Cancer Models. Cancer Immunology, Immunotherapy, 73, 2143-2156.
[31] Amgen Inc (2023) Tarlatamab (DLL3 × CD3 Bispecific Antibody) in Patients with Advanced Small Cell Lung Cancer: Updated Phase II DeLLphi-301 Study Results. New England Journal of Medicine, 389, 2345-2356.

为你推荐